Takahiro Kogawa

Articles by Takahiro Kogawa

8 Datopotamab Deruxtecan (Dato-DXd) in Advanced Triple- Negative Breast Cancer (TNBC): Updated Results From the Phase 1 TROPION-PanTumor01 Study

ByAditya Bardia, MD, MPH, FASCO,Ian E. Krop,Funda Meric-Bernstam, MD,Anthony W. Tolcher,Toru Mukohara,Aaron Lisberg,Toshio Shimizu,Erika P. Hamilton, MD,Alexander Spira, MD, PhD, FACP,Takahiro Kogawa

April 28th 2023

9 Phase 1 TROPION-PanTumor01 Study Evaluating Datopotamab Deruxtecan (Dato-DXd) in Unresectable or Metastatic Hormone Receptor–Positive/ Human Epidermal Growth Factor Receptor 2–Negative Breast Cancer

ByAditya Bardia, MD, MPH, FASCO,Ian E. Krop,Dejan Juric,Takahiro Kogawa,Erika P. Hamilton, MD,Alexander Spira, MD, PhD, FACP,Toru Mukohara,Takuya Tsunoda,Senthil Damodaran,Funda Meric-Bernstam, MD

April 28th 2023

Latest Updated Articles

Trending on CancerNetwork

Setting Up an HDR Brachytherapy Program Amid a National Decline

Biomarker Sequencing, PD-L1 Status, and FLOT Dosing in Gastroesophageal Cancer

Zamto-Cel Improves EFS vs R-GemOx in Transplant-Ineligible R/R LBCL

CD38-Targeted Immuno-PET Helps Detect Active Multiple Myeloma

16-Fraction PMRT With IMN Irradiation Noninferior in High-Risk Breast Cancer